Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259714 · ClinicalTrials.gov registry record · Phase 1
Dialysate Sodium Individualization in Hemodialysis
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00259714 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 1 participants.
The verdict
NCT00259714, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Salt and water excess is an essential mechanism of hypertension. This is particularly relevant to patients with end stage kidney disease (ESKD) on dialysis. We have demonstrated that individualization of the sodium concentration in the dialysate as to match the patient's own serum sodium concentration leads to less thirst, interdialytic weight gain, and better BP control in hypertensive patients. In this study we will evaluate the mechanisms underlying this response by measuring systemic hemodynamics, body volume spaces, and biochemical marker of volume status.
Interventions
- DRUG dialysate sodium individualization
- DRUG standard dialysate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00259714
The ClinicalTrials.gov registry entry for NCT00259714 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dialysate sodium individualization is the first listed.
NCT00259714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00259714 about?
NCT00259714 is a clinical study titled "Dialysate Sodium Individualization in Hemodialysis". Salt and water excess is an essential mechanism of hypertension. This is particularly relevant to patients with end stage kidney disease (ESKD) on dialysis. We have demonstrated that individualization of the sodium concentration in the dialysate as to match the patient's own serum sodium concentrati...
What is the current status of trial NCT00259714?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2006-03. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00259714?
The interventions under investigation include: dialysate sodium individualization (DRUG), standard dialysate sodium (DRUG).
Who is sponsoring clinical trial NCT00259714?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.